Abstract
Pulmonary embolism (PE) is a common and life-threatening cardiovascular emergency. It is a major cause of morbidity and mortality associated with surgery, injury, and medical illnesses. However, PE may occur in patients without any identifiable predisposing factors. The first and most crucial step in the diagnosis of PE is evaluating the likelihood of the disease based on clinical presentation. The appropriate diagnostic algorithm and the interpretation of diagnostic tests will depend on clinical probability of PE. For normotensive patients with clinically suspected PE, multidetector CT pulmonary angiography is currently the most frequently performed imaging test. Current guidelines emphasize the need to combine this test with assessment of clinical probability and D-dimer testing. As a general rule, anticoagulation with heparin should be initiated without delay in all patients with confirmed PE and should be considered in patients with an intermediate or high clinical probability while awaiting the results of further diagnostic confirmation. Thrombolytic agents rapidly resolve thrombus-related vascular obstruction providing instant hemodynamic relief in the majority of patients with massive PE. For patients with massive PE, in whom thrombolysis has failed or is absolutely contraindicated, surgical embolectomy or alternatively percutaneous catheter thrombectomy is recommended as a lifesaving treatment option. Oral anticoagulants (vitamin K antagonists) should be initiated as soon as possible in all hemodynamically stable patients, preferably on the same day as heparin. New oral anticoagulants seem to be as effective as vitamin K antagonists for the treatment and prevention of venous thromboembolism and PE with possibly improved safety profiles.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4–8.
Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–315.
Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578–89.
Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006;332:215–9.
Cohen AT, Agnelli G, Anderson FA et al.; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.
Konstantinides S, Kasper W. Pulmonary embolism. In: Crawford MH, DiMarco JP, Paulus WJ, editors. Cardiology. 3rd ed. London: Elsevier; 2011.
Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med. 1998;158:1369–73.
Wagenvoort CA. Pathology of pulmonary thromboembolism. Chest. 1995;107:10S–7.
Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130:172–5.
Lankeit M, Konstantinides S. Mortality risk assessment and the role of thrombolysis in pulmonary embolism. Crit Care Clin. 2011;27:953–67, vii–viii.
Miniati M, Prediletto R, Formichi B, et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 1999;159:864–71.
Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416–20.
Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144:165–71.
Perrier A, Roy PM, Sanchez O, et al. Multidetector-row computed tomography insuspected pulmonary embolism. N Engl J Med. 2005;352:1760–8.
van Belle A, Büller HR, Huisman MV et al.; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295:172–9.
Becattini C, Agnelli G, Vedovati MC, et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J. 2011;32:1657–63.
Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354:2317–27.
Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007;298:2743–53.
Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000;84:548–52.
Barrit DW, Jordan SC. Anticoagulant treatment of pulmonary embolism: a case controlled study. Lancet. 1960;1:1309–12.
Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. 2008;359:2804–13.
Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17.
Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110:744–9.
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–50.
The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J. 2012;163:33–38.e1.
Meneveau N, Séronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043–50.
Lankeit M, Konstantinides S. Is it time for home treatment of pulmonary embolism ? Eur Respir J. 2012;40(3):742–9.
Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013. [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Apostolakis, S.Z., Konstantinides, S.V. (2014). Acute Pulmonary Embolism. In: Stergiopoulos, K., Brown, D. (eds) Evidence-Based Cardiology Consult. Springer, London. https://doi.org/10.1007/978-1-4471-4441-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4441-0_21
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4440-3
Online ISBN: 978-1-4471-4441-0
eBook Packages: MedicineMedicine (R0)